Skip to main content
. 2020 Jul 7;25(9):674–685. doi: 10.1007/s10495-020-01620-6

Fig. 4.

Fig. 4

Chelerythrine blunts costunolide-induced annexin V-binding and erythrocyte shrinkage. Human erythrocytes were preincubated with the PKC-α inhibitor chelerythrine and then treated with 80 µM costunolide for 24 h. Original histograms of annexin V-binding (a), original histograms of forward scatter (FCS) (b), concentration-dependent decrease of costunolide-induced annexin V-binding (c), and concentration-dependent increase of forward scatter (FCS) of costunolide-shrunken erythrocytes (d) after treatment of human erythrocytes as described above are shown. Number of independent experiments: n = 3. Differences of the means were considered to be statistically significant when the calculated p value was less than 0.05 (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Chel: chelerythrine; Cos: costunolide